KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2016 - 2025)

Alnylam Pharmaceuticals' Share-based Compensation history spans 17 years, with the latest figure at $71.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 21.84% year-over-year to $71.6 million; the TTM value through Dec 2025 reached $348.2 million, up 27.99%, while the annual FY2025 figure was $348.2 million, 27.99% up from the prior year.
  • Share-based Compensation reached $71.6 million in Q4 2025 per ALNY's latest filing, down from $108.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $128.1 million in Q3 2022 to a low of $29.3 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $61.9 million, with a median of $50.7 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 283.97% in 2022, then crashed 50.1% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $44.6 million in 2021, then decreased by 4.07% to $42.8 million in 2022, then fell by 1.81% to $42.0 million in 2023, then surged by 118.23% to $91.6 million in 2024, then fell by 21.84% to $71.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Share-based Compensation are $71.6 million (Q4 2025), $108.2 million (Q3 2025), and $111.7 million (Q2 2025).